| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07c9542186133097bd6bbb7d92393090 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K17-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-595
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 |
| filingDate |
2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77e108af33cd9740a2fca4febe00ff7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_295df261e8b818cda7dab6e831c0d277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_925b4123b1325c2874d5385fe62cc038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_613ac0817a1ec5a938946fdfe5c8ba7b |
| publicationDate |
2020-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020276130-A1 |
| titleOfInvention |
Therapeutic cationic peptides and unimolecular nanoparticles for efficient delivery thereof |
| abstract |
Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be used in the treatment of breast cancer and other diseases or conditions in which PKM2 is overexpressed. Such PKM2 peptides may be delivered to cancer cells using pH sensitive unimolecular nanoparticles comprising anionic polymers. |
| priorityDate |
2017-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |